世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

病院感染症検査市場レポート:適応症別(UTI(尿路感染症)、SSI(手術部位感染症)、肺炎、血流感染症、MRSA(メチシリン耐性黄色ブドウ球菌)、その他)、地域別 2024-2032


Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2024-2032

世界の院内感染検査市場規模は2023年に121億米ドルに達した。今後、IMARC Groupは、市場は2032年までに466億米ドルに達し、2024年から2032年の間に15.6%の成長率(CAGR)を示すと予測している。 院内感染(HAI... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
IMARC Services Private Limited.
アイマークサービス
2024年1月30日 US$3,899
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
143 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

世界の院内感染検査市場規模は2023年に121億米ドルに達した。今後、IMARC Groupは、市場は2032年までに466億米ドルに達し、2024年から2032年の間に15.6%の成長率(CAGR)を示すと予測している。

院内感染(HAI)または院内感染症は、病院や診療所で発症する疾患である。院内感染とは、病院内で発生する感染症や病気を意味する。特別養護老人ホーム、リハビリテーションセンター、病院、その他の臨床環境の近くでも、このような病気にかかる可能性がある。ほとんどの人は集中治療室(ICU)や救急治療室(ER)にいるときにHAIに感染する。一般的に、これらの疾患の潜伏期間は、患者が入院してから48時間から4日の間である。院内感染の主な原因は、病院内のスタッフが適切な衛生管理を行っていないことである。その他の理由としては、メンテナンスの不備、病院スタッフの自己満足、多剤耐性菌(MDRO)の増加などが挙げられる。最もよく発生する院内感染には、肺炎、一次血流感染、尿路感染などがある。多くの場合、これらの院内感染症は患者自身のマイクロバイオームに起因することもあることがわかっている。特に外科手術の後など、皮膚保護層が脅威となりうるものと接触し、感染を引き起こすことで起こる。

市場動向:
人口の増加と医療インフラの近代化により、世界中で医療施設の数が大幅に増加している。その結果、HAIの発生率が上昇し、院内感染検査の需要を牽引している。さらに、高度な技術と科学的革新により、マイクロアレイ、ポリメラーゼ連鎖反応(PCR)、リアルタイム・ロケーション・システム(RTLS)、固相ハイブリダイゼーションなど、HAIの予防、診断、モニタリングのためのさまざまな技術が現在市場で入手可能になっている。RTLSのような技術は、患者とスタッフの両方におけるHAIの蔓延を防ぐことを容易にする。患者の間でのHAIに対する意識の高まりや、HAIの発生率が高い病院を罰する規制を制定する政府の動きは、市場の成長を促進する他の要因の一部である。

主な市場セグメンテーション
IMARC Groupは、世界の病院後天性疾患検査市場レポートの各サブセグメントにおける主要動向の分析と、2024年から2032年までの世界および地域レベルでの予測を提供しています。当レポートでは、適応症に基づいて市場を分類しています。

適応症別の内訳

UTI(尿路感染症)
SSI(手術部位感染)
肺炎
血流感染
MRSA(メチシリン耐性黄色ブドウ球菌)
その他

適応症に基づき、市場は尿路感染、手術部位感染、肺炎、血流感染、メチシリン耐性黄色ブドウ球菌、その他に区分される。現在、尿路感染症が最大のセグメントを占めている。

地域別の洞察

北米
欧州
アジア太平洋
中東・アフリカ
ラテンアメリカ

地域別に見ると、市場は北米、欧州、アジア太平洋、中東・アフリカ、中南米に区分される。

競争環境:
市場の競争環境も調査されており、主なプレーヤーとしては、Abbott Laboratories, Alere, Inc.、Becton, Dickinson and Company、bioMérieux SA、F. Hoffmann-La Roche Ltd.、Hologic, Inc.、QIAGEN、Siemens Healthcare、Diatherix Laboratories, Inc.、Meridian Bioscience, Inc.、Thermo Fisher Scientific, Inc. (Life Technologies Corporation)、Cepheid, Inc.などが挙げられる。

本レポートは、世界の院内感染検査市場について、その重要な側面をすべて網羅した深い洞察を提供します。その内容は、市場のマクロ的な概要から、業界実績のミクロ的な詳細、最近の動向、主要な市場促進要因と課題、SWOT分析、ポーターの5つの力分析、バリューチェーン分析など多岐にわたります。本レポートは、起業家、投資家、研究者、コンサルタント、ビジネス戦略家、および何らかの形で院内感染検査市場に参入する、または参入を計画しているすべての人々にとって必読の書です。

本レポートで扱う主な質問

1.2023年の世界院内感染検査市場規模は?
2.病院後天性疾患検査の世界市場成長率2024-2032年は?
3.世界の病院後天性疾患検査市場の促進要因は?
4.世界の病院後天性疾患検査市場における主要な業界動向は?
5.COVID-19が世界の病院後天性疾患検査市場に与える影響は?
6.世界の病院後天性疾患検査市場の適応症別内訳は?
7.病院後天性疾患検査の世界市場における主要地域は?
8.世界の病院後天性疾患検査市場における主要企業/プレーヤーは?

ページTOPに戻る


目次

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hospital Acquired Disease Testing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Indication
5.5 Market Breakup by Region
5.6 Market Forecast
5.7 SWOT Analysis
5.7.1 Overview
5.7.2 Strengths
5.7.3 Weaknesses
5.7.4 Opportunities
5.7.5 Threats
5.8 Value Chain Analysis
5.9 Porters Five Forces Analysis
5.9.1 Overview
5.9.2 Bargaining Power of Buyers
5.9.3 Bargaining Power of Suppliers
5.9.4 Degree of Competition
5.9.5 Threat of New Entrants
5.9.6 Threat of Substitutes
5.10 Price Analysis
6 Market Breakup by Indication
6.1 UTI (Urinary Tract Infection)
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 SSI (Surgical Site Infection)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Pneumonia
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Bloodstream Infections
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Region
7.1 North America
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Europe
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Asia Pacific
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Middle East and Africa
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Latin America
7.5.1 Market Trends
7.5.2 Market Forecast
8 Competitive Landscape
8.1 Market Structure
8.2 Key Players
8.3 Profiles of Key Players
8.3.1 Abbott Laboratories
8.3.2 Alere, Inc.
8.3.3 Becton, Dickinson and Company
8.3.4 bioMérieux SA
8.3.5 F. Hoffmann-La Roche Ltd.
8.3.6 Hologic, Inc.
8.3.7 QIAGEN
8.3.8 Siemens Healthcare
8.3.9 Diatherix Laboratories, Inc.
8.3.10 Meridian Bioscience, Inc.
8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
8.3.12 Cepheid, Inc.
List of Figures
Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2023
Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2023
Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
Figure 7: Global: Hospital Acquired Disease Testing Industry: Value Chain Analysis
Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter’s Five Forces Analysis
Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
List of Tables
Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million US$), 2024-2032
Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
Table 5: Global: Hospital Acquired Disease Testing Market: Key Players

 

ページTOPに戻る


 

Summary

The global hospital acquired disease testing market size reached US$ 12.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 46.6 Billion by 2032, exhibiting a growth rate (CAGR) of 15.6% during 2024-2032.

Hospital-acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital-acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Other reasons can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patient's own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.

Market Trends:
Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hospital acquired disease testing market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on indication.

Breakup by Indication:

UTI (Urinary Tract Infection)
SSI (Surgical Site Infection)
Pneumonia
Bloodstream Infections
MRSA (Methicillin-Resistant Staphylococcus Aureus)
Others

Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.

Regional Insights:

North America
Europe
Asia Pacific
Middle East and Africa
Latin America

Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Competitive Landscape:
The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.

This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.

Key Questions Answered in This Report

1. What is the market size for the global hospital acquired disease testing market 2023?
2. What is the global hospital acquired disease testing market growth 2024-2032?
3. What are the global hospital acquired disease testing market drivers?
4. What are the key industry trends in the global hospital acquired disease testing market?
5. What is the impact of COVID-19 on the global hospital acquired disease testing market?
6. What is the global hospital acquired disease testing market breakup by indication?
7. What are the major regions in the global hospital acquired disease testing market?
8. Who are the key companies/players in the global hospital acquired disease testing market?



ページTOPに戻る


Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hospital Acquired Disease Testing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Indication
5.5 Market Breakup by Region
5.6 Market Forecast
5.7 SWOT Analysis
5.7.1 Overview
5.7.2 Strengths
5.7.3 Weaknesses
5.7.4 Opportunities
5.7.5 Threats
5.8 Value Chain Analysis
5.9 Porters Five Forces Analysis
5.9.1 Overview
5.9.2 Bargaining Power of Buyers
5.9.3 Bargaining Power of Suppliers
5.9.4 Degree of Competition
5.9.5 Threat of New Entrants
5.9.6 Threat of Substitutes
5.10 Price Analysis
6 Market Breakup by Indication
6.1 UTI (Urinary Tract Infection)
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 SSI (Surgical Site Infection)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Pneumonia
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Bloodstream Infections
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Region
7.1 North America
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Europe
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Asia Pacific
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Middle East and Africa
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Latin America
7.5.1 Market Trends
7.5.2 Market Forecast
8 Competitive Landscape
8.1 Market Structure
8.2 Key Players
8.3 Profiles of Key Players
8.3.1 Abbott Laboratories
8.3.2 Alere, Inc.
8.3.3 Becton, Dickinson and Company
8.3.4 bioMérieux SA
8.3.5 F. Hoffmann-La Roche Ltd.
8.3.6 Hologic, Inc.
8.3.7 QIAGEN
8.3.8 Siemens Healthcare
8.3.9 Diatherix Laboratories, Inc.
8.3.10 Meridian Bioscience, Inc.
8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
8.3.12 Cepheid, Inc.
List of Figures
Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2023
Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2023
Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
Figure 7: Global: Hospital Acquired Disease Testing Industry: Value Chain Analysis
Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter’s Five Forces Analysis
Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
List of Tables
Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million US$), 2024-2032
Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
Table 5: Global: Hospital Acquired Disease Testing Market: Key Players

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

IMARC Services Private Limited.社の医療分野での最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


IMARC Services Private Limited.社はどのような調査会社ですか?


インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る